Title: Development of novel class of compounds for eye delivery to stop neurodegeneration in glaucoma
Description of the Project: A French pre-clinical stage start-up develops novel solutions to treat neurodegeneration, a process linked with microtubule disorders. It develops compounds to restore microtubule stability. One application is stopping neurodegeneration of the optic nerve in glaucoma, the leading cause of irreversible blindness. The company seeks partners specialized in biopolymers and/or surface chemistry to develop drug formulation and delivery solutions into the eye under research or technical agreements.
Partner Sought: SMEs and pharma industries with an expertise in biopolymers and/or surface chemistry are being sought for drug formulation.
Deadline: 07/04/2020
Contact: GAIN - Galactea Plus
galactea.gain@xunta.es
Publicado por europa en septiembre 11, 2019
